Chinese mRNA vaccine developer Suzhou Abogen Biosciences Co Ltd has raised as much as $300 million in its Series C+ round of funding, per an announcement.
SoftBank Vision Fund alongside returning investor 5Y Capital jointly led the funding.
Vaccine products
Chinese mRNA vaccine developer Suzhou Abogen Biosciences Co Ltd has raised as much as $300 million in its Series C+ round of funding, per an announcement.
SoftBank Vision Fund alongside returning investor 5Y Capital jointly led the funding.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@delastreetasia.com